Advertisement

Retinal Degenerative Diseases

Mechanisms and Experimental Therapy

  • John D. Ash
  • Robert E. Anderson
  • Matthew M. LaVail
  • Catherine Bowes Rickman
  • Joe G. Hollyfield
  • Christian Grimm
Conference proceedings

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1074)

Table of contents

  1. Front Matter
    Pages i-xlii
  2. Age-Related Macular Degeneration (AMD)

  3. Gene Therapies

    1. Front Matter
      Pages 67-67
    2. Cécile Fortuny, John G. Flannery
      Pages 75-81
    3. Alejandro Garanto, Saskia D. van der Velde-Visser, Frans P. M. Cremers, Rob W. J. Collin
      Pages 83-89
    4. Sophia-Martha kleine Holthaus, Alexander J. Smith, Sara E. Mole, Robin R. Ali
      Pages 91-99
    5. Susanne F. Koch, Stephen H. Tsang
      Pages 101-107
    6. Rahel Zulliger, Jamie N. Watson, Muayyad R. Al-Ubaidi, Linas Padegimas, Ozge Sesenoglu-Laird, Mark J. Cooper et al.
      Pages 109-115
    7. Yuhong Wang, Ammaji Rajala, Raju V. S. Rajala
      Pages 117-123
    8. Fan Yang, Hongwei Ma, Sanford L. Boye, William W. Hauswirth, Xi-Qin Ding
      Pages 125-131
  4. In-Vivo Diagnostics for Structure and Function

    1. Front Matter
      Pages 133-133
    2. Soon K. Cheong, Wenjun Xiong, Jennifer M. Strazzeri, Constance L. Cepko, David R. Williams, William H. Merigan
      Pages 135-144
    3. Marci L. DeRamus, Timothy W. Kraft
      Pages 145-150
    4. Alison Huckenpahler, Melissa Wilk, Brian Link, Joseph Carroll, Ross Collery
      Pages 151-156
  5. Inflammation and Angiogenesis

    1. Front Matter
      Pages 175-175
    2. Maya Barben, Marijana Samardzija, Christian Grimm
      Pages 177-183
    3. Michael T. Massengill, Chulbul M. Ahmed, Alfred S. Lewin, Cristhian J. Ildefonso
      Pages 185-191
    4. John R. Heckenlively, Steven K. Lundy
      Pages 193-201
    5. Abdoulaye Sene, Rajendra S. Apte
      Pages 203-208
    6. Hideto Koso, Ryuichi Nishinakamura, Sumiko Watanabe
      Pages 209-215
  6. Inherited Retinal Degenerations

    1. Front Matter
      Pages 217-217
    2. Pooja Biswas, Muhammad Asif Naeem, Muhammad Hassaan Ali, Muhammad Zaman Assir, Shaheen N. Khan, Sheikh Riazuddin et al.
      Pages 219-228
    3. Kari Branham, Aditya A. Guru, Igor Kozak, Pooja Biswas, Mohammad Othman, Kameron Kishaba et al.
      Pages 229-236
    4. Stephen P. Daiger, Sara J. Bowne, Lori S. Sullivan, Kari Branham, Dianna K. Wheaton, Kaylie D. Jones et al.
      Pages 237-245
    5. J. A. Thompson, J. N. De Roach, T. L. McLaren, T. M. Lamey
      Pages 265-271
  7. Mechanisms of Degeneration

    1. Front Matter
      Pages 273-273
    2. Larissa Ikelle, Muna I. Naash, Muayyad R. Al-Ubaidi
      Pages 275-280
    3. Hwa Sun Kim, Shun-Ping Huang, Eun-Jin Lee, Cheryl Mae Craft
      Pages 281-287
    4. Jianhai Du, Jie An, Jonathan D. Linton, Yekai Wang, James B. Hurley
      Pages 289-295
    5. Anna B. Graca, Claire Hippert, Rachael A. Pearson
      Pages 303-308
    6. Karina E. Guziewicz, Emily McTish, Valerie L. Dufour, Kathryn Zorych, Anuradha Dhingra, Kathleen Boesze-Battaglia et al.
      Pages 309-315
    7. Christin Hanke-Gogokhia, Jeanne M. Frederick, Houbin Zhang, Wolfgang Baehr
      Pages 317-325
    8. Maria Iribarne, Ichiro Masai
      Pages 327-333
    9. Gulpreet Kaur, Aparna Lakkaraju
      Pages 335-343
    10. Kenkichi Baba, Christophe P. Ribelayga, P. Michael Iuvone, Gianluca Tosini
      Pages 345-350

About these proceedings

Introduction

The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the “best” and “most important” meetings in the field.

The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy.

While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2014. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials.

The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS.

Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2018 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.

Keywords

animal models oxidative stress carotenoids photoreceptor macular degeneration inflammation gene therapy

Editors and affiliations

  • John D. Ash
    • 1
  • Robert E. Anderson
    • 2
  • Matthew M. LaVail
    • 3
  • Catherine Bowes Rickman
    • 4
  • Joe G. Hollyfield
    • 5
  • Christian Grimm
    • 6
  1. 1.Department of OphthalmologyUniversity of FloridaGainesvilleUSA
  2. 2.Ophthalmology and Cell BiologyUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA
  3. 3.School of Medicine Beckman Vision CenterUniversity of California San FranciscoSan FranciscoUSA
  4. 4.Departments of Ophthalmology and Cell BiologyDuke Eye Center, Duke University Medical CenterDurhamUSA
  5. 5.Division of OphthalmologyCase Western Reserve UniversityClevelandUSA
  6. 6.Department of OphthalmologyUniversity Hospital ZurichZurichSwitzerland

Bibliographic information

Industry Sectors
Biomedicine
Pharma
Health & Hospitals
Biotechnology